Download PDF
Am J Perinatol 2022; 39(S 01): S23-S25
DOI: 10.1055/s-0042-1757351
Review Article

Extracellular Vesicles: A New Promise for the Prevention of Bronchopulmonary Dysplasia

Luca Bonadies
1   Department of Woman's and Child's Health, Neonatal Intensive Care Unit, University of Padova, Padova, Italy
2   Department of Woman's and Child's Health, Institute of Pediatric Research, “Città della Speranza”, Italy
,
Beatrice De Vos
3   Clinical Research Consultant, Belgium
,
Maurizio Muraca
2   Department of Woman's and Child's Health, Institute of Pediatric Research, “Città della Speranza”, Italy
4   Department of Women's and Children's Health, Stem Cell and Regenerative Medicine Laboratory, University of Padova, Padova, Italy
,
Eugenio Baraldi
1   Department of Woman's and Child's Health, Neonatal Intensive Care Unit, University of Padova, Padova, Italy
2   Department of Woman's and Child's Health, Institute of Pediatric Research, “Città della Speranza”, Italy
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Bronchopulmonary dysplasia (BPD) despite numerous efforts of neonatologists remains one of the most frequent and long-lasting chronic respiratory diseases consequent to extreme preterm birth. New clinical trials are exploring the possible use of mesenchymal stem cells (MSCs) and especially their products, extracellular vesicles (EVs), that overcome some of the possible issues related to the use of live cells. MSCs already reached clinical implementation; MSC-EVs, on the contrary, showed extremely promising results in the preclinical setting but are still waiting their first in human results that are likely to happen soon.

Key Points

  • BPD is one of the most frequent complications of preterm birth, and its prevention lacks an effective tool.

  • EVs have shown encouraging results in preclinical animal models.

  • Technical and biological advancements are needed before routine clinical use.

Keywords

bronchopulmonary dysplasia - extracellular vesicles - hyperoxia - prevention - mesenchymal stem cells - preterm infants - chronic disease - clinical trial - animal models


Publication History

Received: 05 July 2022

Accepted: 18 August 2022

Article published online:
10 November 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med 2007; 357 (19) 1946-1955
    CrossrefPubMedGoogle Scholar
  • 2 Bonadies L, Zaramella P, Porzionato A, Perilongo G, Muraca M, Baraldi E. Present and future of bronchopulmonary dysplasia. J Clin Med 2020; 9 (05) 1539
    CrossrefPubMedGoogle Scholar
  • 3 Jobe AH, Bancalari E. An all-inclusive perspective on bronchopulmonary dysplasia. J Pediatr 2021; 234: 257-259
    CrossrefPubMedGoogle Scholar
  • 4 Augustine S, Avey MT, Harrison B. et al. Mesenchymal stromal cell therapy in bronchopulmonary dysplasia: systematic review and meta-analysis of preclinical studies. Stem Cells Transl Med 2017; 6 (12) 2079-2093
    CrossrefPubMedGoogle Scholar
  • 5 Chang YS, Ahn SY, Yoo HS. et al. Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. J Pediatr 2014; 164 (05) 966-972.e6
    CrossrefPubMedGoogle Scholar
  • 6 Powell SB, Silvestri JM. Safety of intratracheal administration of human umbilical cord blood derived mesenchymal stromal cells in extremely low birth weight preterm infants. J Pediatr 2019; 210 (00) 209-213.e2
    CrossrefPubMedGoogle Scholar
  • 7 Lim R, Malhotra A, Tan J. et al. First-in-human administration of allogeneic amnion cells in premature infants with bronchopulmonary dysplasia: a safety study. Stem Cells Transl Med 2018; 7 (09) 628-635
    CrossrefPubMedGoogle Scholar
  • 8 Ahn SY, Chang YS, Kim JH, Sung SI, Park WS. Two-year follow-up outcomes of premature infants enrolled in the phase I trial of mesenchymal stem cells transplantation for bronchopulmonary dysplasia. J Pediatr 2017; 185: 49-54.e2
    CrossrefPubMedGoogle Scholar
  • 9 Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med 2019; 4 (01) 22
    CrossrefPubMedGoogle Scholar
  • 10 van Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol 2018; 19 (04) 213-228
    CrossrefPubMedGoogle Scholar
  • 11 Li W, Ren G, Huang Y. et al. Mesenchymal stem cells: a double-edged sword in regulating immune responses. Cell Death Differ 2012; 19 (09) 1505-1513
    CrossrefPubMedGoogle Scholar
  • 12 Madhusoodanan J. The therapeutic potential of exosomes. Nature 2020; 581 (7807): S10-S11
    CrossrefPubMedGoogle Scholar
  • 13 Willis GR, Fernandez-Gonzalez A, Anastas J. et al. Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation. Am J Respir Crit Care Med 2018; 197 (01) 104-116
    CrossrefPubMedGoogle Scholar
  • 14 Willis GR, Fernandez-Gonzalez A, Reis M. et al. Mesenchymal stromal cell-derived small extracellular vesicles restore lung architecture and improve exercise capacity in a model of neonatal hyperoxia-induced lung injury. J Extracell Vesicles 2020; 9 (01) 1790874
    CrossrefPubMedGoogle Scholar
  • 15 Willis GR, Reis M, Gheinani AH. et al. Extracellular vesicles protect the neonatal lung from hyperoxic injury through the epigenetic and transcriptomic reprogramming of myeloid cells. Am J Respir Crit Care Med 2021; 204 (12) 1418-1432
    CrossrefPubMedGoogle Scholar
  • 16 Braun RK, Chetty C, Balasubramaniam V. et al. Intraperitoneal injection of MSC-derived exosomes prevent experimental bronchopulmonary dysplasia. Biochem Biophys Res Commun 2018; 503 (04) 2653-2658
    CrossrefPubMedGoogle Scholar
  • 17 Ai D, Shen J, Sun J. et al. Mesenchymal stem cell-derived extracellular vesicles suppress hyperoxia-induced transdifferentiation of rat alveolar type 2 epithelial cells. Stem Cells Dev 2022; 31 (3-4): 53-66
    CrossrefPubMedGoogle Scholar
  • 18 Porzionato A, Zaramella P, Dedja A. et al. Intratracheal administration of clinical-grade mesenchymal stem cell-derived extracellular vesicles reduces lung injury in a rat model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2019; 316 (01) L6-L19
    CrossrefPubMedGoogle Scholar
  • 19 Porzionato A, Zaramella P, Dedja A. et al. Intratracheal administration of mesenchymal stem cell-derived extracellular vesicles reduces lung injuries in a chronic rat model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2021; 320 (05) L688-L704
    CrossrefPubMedGoogle Scholar
  • 20 Ahn SY, Park WS, Kim YE. et al. Vascular endothelial growth factor mediates the therapeutic efficacy of mesenchymal stem cell-derived extracellular vesicles against neonatal hyperoxic lung injury. Exp Mol Med 2018; 50 (04) 1-12
    CrossrefPubMedGoogle Scholar
  • 21 Li Z, Gong X, Li D, Yang X, Shi Q, Ju X. Intratracheal transplantation of amnion-derived mesenchymal stem cells ameliorates hyperoxia-induced neonatal hyperoxic lung injury via aminoacyl-peptide hydrolase. Int J Stem Cells 2020; 13 (02) 221-236
    CrossrefPubMedGoogle Scholar
  • 22 Lithopoulos MA, Strueby L, O'Reilly M. et al. Pulmonary and neurologic effects of mesenchymal stromal cell extracellular vesicles in a multifactorial lung injury model. Am J Respir Crit Care Med 2022; 205 (10) 1186-1201
    CrossrefPubMedGoogle Scholar
  • 23 Abele AN, Taglauer ES, Almeda M. et al. Antenatal mesenchymal stromal cell extracellular vesicle treatment preserves lung development in a model of bronchopulmonary dysplasia due to chorioamnionitis. Am J Physiol Lung Cell Mol Physiol 2022; 322 (02) L179-L190
    CrossrefPubMedGoogle Scholar
  • 24 Khalaj K, Antounians L, Figueira RL, Post M, Zani A. Autophagy is impaired in fetal hypoplastic lungs and rescued by administration of amniotic fluid stem cell extracellular vesicles. Am J Respir Crit Care Med 2022; 206 (04) 476-487
    CrossrefPubMedGoogle Scholar
  • 25 Lesage F, Thébaud B. Mesenchymal stromal cell-derived extracellular vesicles for neonatal lung disease: tiny particles, major promise, rigorous requirements for clinical translation. Cells 2022; 11 (07) 1176
    CrossrefPubMedGoogle Scholar